2025–2029 Retinal Disorder Treatment Market Outlook: Regional Trends and Growth Forecast
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
Claim your 30% discount on Global Market Reports with code ONLINE30. Limited time only.
What CAGR Is Anticipated for the Retinal Disorder Treatment Market Through 2029?
The market for histone deacetylase inhibitors has experienced robust growth in the past few years. Its size is projected to increase from $1.2 billion in 2024 to $1.29 billion in 2025, with a compound annual growth rate (CAGR) of 7.2%. This growth during the historic period can be credited to factors such as regulatory backing and accelerated approvals, rising incidence of cancer, enhanced funding for cancer research, broadening of therapeutic applications, and increased spending on healthcare infrastructure.
The market for histone deacetylase inhibitors is projected to witness robust expansion in the coming years. It is anticipated to reach “$1.71 billion by 2029, with a CAGR of 7.2%. The increased biotechnology investments, the surge of the elderly population, the positive reception of regulatory approvals, expedited drug approval procedures, enhanced drug delivery systems, and the broadening of therapeutic applications can all contribute to growth during the forecast period. The forecast period will also observe major trends including the incorporation of wearable devices to track patient health, breakthroughs in nanotechnology and drug delivery techniques, progress in recognising and verifying biomarkers, the rise of artificial intelligence (AI) and machine learning, and the advent of next-generation sequencing.
Download The Free Sample Report Here:
https://www.thebusinessresearchcompany.com/sample.aspx?id=17170&type=smp
What Market Forces Are Driving The Retinal Disorder Treatment Sector In 2025 And Beyond?
The rise in instances of retinal ailments is predicted to boost the development of the retinal disorder treatment market in the future. Medical conditions affecting the retina, a light-sensitive tissue at the back of the eye, are referred to as retinal diseases. These can result in vision loss or severe vision impairment. Retinal disorder treatments manage and alleviate the symptoms of these disorders through techniques such as laser therapy, vitrectomy, and retinal implants. For instance, the International Agency for the Prevention of Blindness, based in the UK, projected in January 2023 that age-related macular degeneration (AMD) would account for roughly 5% of global blindness. Furthermore, it is anticipated that age-related macular degeneration diseases will affect 288 million people by 2040. Therefore, the escalating prevalence of retinal disorders fuels the growth of the retinal disorder treatment market.
The histone deacetylase inhibitors market covered in this report is segmented –
1) By Classification: Class I Histone Deacetylases (HDACs), Class II Histone Deacetylases (HDACs), Class III Histone Deacetylases (HDACs), Other Classifications
2) By Route Of Administration: Oral, Injectable, Other Routes Of Administration
3) By Distribution Channel: Hospital Pharmacy, Online Pharmacy, Retail Pharmacy, Other Distribution Channels
4) By Application: Oncology, Neurology, Other Applications
5) By End Users: Hospitals, Homecare, Specialty Clinics, Other End Users
Subsegments:
1) By Class I Histone Deacetylases (HDACs): HDAC1 Inhibitors, HDAC2 Inhibitors, HDAC3 Inhibitors, HDAC8 Inhibitors
2) By Class II Histone Deacetylases (HDACs): HDAC4 Inhibitors, HDAC5 Inhibitors, HDAC6 Inhibitors, HDAC7 Inhibitors, HDAC9 Inhibitors, HDAC10 Inhibitors
3) By Class III Histone Deacetylases (HDACs): Sirtuin 1 (SIRT1) Inhibitors, Sirtuin 2 (SIRT2) Inhibitors, Sirtuin 3 (SIRT3) Inhibitors, Sirtuin 4 (SIRT4) Inhibitors, Sirtuin 5 (SIRT5) Inhibitors, Sirtuin 6 (SIRT6) Inhibitors, Sirtuin 7 (SIRT7) Inhibitors
4) By Other Classifications: Dual-acting HDAC Inhibitors, Pan-HDAC Inhibitors, Selective HDAC Inhibitors, Combination Inhibitors (HDAC + Other Mechanisms)
What Upcoming Trends Are Expected To Impact The Retinal Disorder Treatment Market Globally?
Leading businesses in the histone deacetylase inhibitors market are honing their focus on creating standout product formulations like oral histone deacetylase (HDAC) inhibitors, to diversify treatment alternatives and enhance patient ease and adherence. Oral histone deacetylase (HDAC) inhibitors are orally administered drugs targeting HDAC enzymes that manage gene regulation, and are considered potential treatments for numerous diseases, including cancer and inflammatory ailments. For example, Italfarmaco S.p.A., a pharmaceutical company based in Italy, had its oral histone deacetylase (HDAC) inhibitor, Duvyzat (givinostat), approved by the Food and Drug Administration for Duchenne muscular dystrophy (DMD) treatment in patients six years and older in March 2024. Duvyzat works by restraining the progression of events leading to muscle damage, potentially limiting the advancement of muscle decay linked with DMD. By keeping the HDAC overactivity in check, the drug lessens inflammation and fibrosis while encouraging muscle fiber regeneration. This approval stems from the critical phase 3 EPIDYS trial, which achieved its major marker, showing that Duvyzat users experienced a statistical aptitude in reducing the time spent to finish the four-stair climb test compared to those on a placebo.
Which Firms Are Considered Leaders In The Retinal Disorder Treatment Market Space?
Major companies operating in the histone deacetylase inhibitors market are Merck & Co. Inc., AstraZeneca plc, Novartis AG, Eisai Co. Ltd., Aurobindo Pharma Limited, Karyopharm Therapeutics Inc., Syndax Pharmaceuticals Inc., MEI Pharma Inc., Italfarmaco S.p.A., Tokyo Chemical Industry Co. Ltd., InvivoGen Corp., Huya Bioscience International LLC, Crystal Genomics Inc., Spectrum Pharmaceuticals Inc., Curis Inc., Celgene Corporation, Celleron Therapeutics, Medivir AB, Onxeo SA, Regenacy Pharmaceuticals Inc., Shenzhen Chipscreen Biosciences Co. Ltd., Wellness Pharma International LLC, Forum Pharmaceuticals Inc., Midatech Pharma PLC
What Role Do Regional Policies And Investments Play In Retinal Disorder Treatment Market Expansion?
North America was the largest region in the histone deacetylase inhibitors market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the histone deacetylase inhibitors market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.
Request For A Customized Report:
https://www.thebusinessresearchcompany.com/customise?id=17170&type=smp
About The Business Research Company:
With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.
Get in touch with us:
The Business Research Company: https://www.thebusinessresearchcompany.com/
Americas +1 310-496-7795
Asia +44 7882 955267 & +91 8897263534
Europe +44 7882 955267
Email us at info@tbrc.info
Follow us on:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model
